
Pfizer's Stake in Sensodyne Maker Haleon Reduced to 24%
Pfizer, the top shareholder of consumer healthcare firm Haleon, is set to reduce its stake in the company to about 24% from the current 32%. The sale of 630 million shares is expected to be worth about 2.03 billion pounds, with an offer price per share to be announced in March. Haleon, known for brands like Sensodyne toothpaste and Advil painkillers, was formed in 2019 through a merger of GSK and Pfizer's consumer healthcare businesses. GSK, the former parent company, has also reduced its stake in Haleon and the London-listed company plans to repurchase shares from Pfizer.


